Colibactin

Colibactin
Names
IUPAC name
2-[6-[(2S)-2-methyl-3,4-dihydro-2H-pyrrol-5-yl]-5-oxo-4-azaspiro[2.4]hept-6-en-7-yl]-N-[[4-[2-[4-[2-[[2-[6-[(2S)-2-methyl-3,4-dihydro-2H-pyrrol-5-yl]-5-oxo-4-azaspiro[2.4]hept-6-en-7-yl]acetyl]amino]acetyl]-1,3-thiazol-2-yl]-2-oxoacetyl]-1,3-thiazol-2-yl]methyl]acetamide
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
KEGG
  • InChI=1S/C37H38N8O7S2/c1-17-3-5-21(40-17)29-19(36(7-8-36)44-33(29)51)11-26(47)38-13-25(46)23-15-54-35(43-23)32(50)31(49)24-16-53-28(42-24)14-39-27(48)12-20-30(22-6-4-18(2)41-22)34(52)45-37(20)9-10-37/h15-18H,3-14H2,1-2H3,(H,38,47)(H,39,48)(H,44,51)(H,45,52)/t17-,18-/m0/s1
    Key: ZWKHDAZPVITMAI-ROUUACIJSA-N
  • C[C@H]1CCC(=N1)C2=C(C3(CC3)NC2=O)CC(=O)NCC4=NC(=CS4)C(=O)C(=O)C5=NC(=CS5)C(=O)CNC(=O)CC6=C(C(=O)NC67CC7)C8=N[C@H](CC8)C
Properties
C37H38N8O7S2
Molar mass 770.88 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Colibactin is a genotoxic metabolite produced by Escherichia coli and other Enterobacteriaceae ("enteric bacteria") believed to cause mutations leading to colorectal cancer and the progression of colorectal cancer.[1][2][3][4] Colibactin is a polyketide peptide that can form interstrand crosslinks in DNA.[2] Colibactin is only produced by bacterial strains containing a polyketide synthase genomic island (pks)[1] or clb biosynthetic gene cluster.[4] About 20% of humans are colonized with E. coli that harbor the pks island.[5]

Colibactin forms DNA inter-strand cross-links by alkylation of adenine moieties on opposing DNA strands.[4] It induces lytic development in certain bacteria that contain prophages.[6] Colibactin has been previously demonstrated to have a characteristic mutational signature.[7] The same mutational signature was discovered in several cohorts of colon cancer patients, and in smaller numbers of patients with urogenital and head and neck cancers.

References

[edit]
  1. ^ a b Arthur JC (2020). "Microbiota and colorectal cancer: colibactin makes its mark". Nature Reviews Gastroenterology & Hepatology. 17 (6): 317–318. doi:10.1038/s41575-020-0303-y. PMID 32317778. S2CID 216033220.
  2. ^ a b Zhou T, Hirayama Y, Watanabe K (2021). "Isolation of New Colibactin Metabolites from Wild-Type Escherichia coli and In Situ Trapping of a Mature Colibactin Derivative". Journal of the American Chemical Society. 143 (14): 5526–5533. doi:10.1021/jacs.1c01495. PMID 33787233. S2CID 232431632.
  3. ^ Helmink BA, Khan M, Wargo JA (2019). "The microbiome, cancer, and cancer therapy". Nature Medicine. 25 (3): 377–388. doi:10.1038/s41591-019-0377-7. PMID 30842679. S2CID 71145949.
  4. ^ a b c Wernke KM, Xue M, Herzon SB (2020). "Structure and bioactivity of colibactin". Bioorganic & Medicinal Chemistry Letters. 30 (15): 127280. doi:10.1016/j.bmcl.2020.127280. PMC 7309967. PMID 32527463.
  5. ^ Balskus EP (2015). "Colibactin: understanding an elusive gut bacterial genotoxin". Natural Product Reports. 32 (11): 1534–40. doi:10.1039/c5np00091b. PMID 26390983.
  6. ^ Silpe, Justin E.; Wong, Joel W. H.; Owen, Siân V.; Baym, Michael; Balskus, Emily P. (2022-02-23). "The bacterial toxin colibactin triggers prophage induction". Nature. 603 (7900): 315–320. Bibcode:2022Natur.603..315S. doi:10.1038/s41586-022-04444-3. ISSN 1476-4687. PMC 8907063. PMID 35197633.
  7. ^ Pleguezuelos-Manzano, Cayetano; Puschhof, Jens; Rosendahl Huber, Axel; van Hoeck, Arne; Wood, Henry M.; Nomburg, Jason; Gurjao, Carino; Manders, Freek; Dalmasso, Guillaume; Stege, Paul B.; Paganelli, Fernanda L.; Geurts, Maarten H.; Beumer, Joep; Mizutani, Tomohiro; Miao, Yi (April 2020). "Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli". Nature. 580 (7802): 269–273. doi:10.1038/s41586-020-2080-8. ISSN 1476-4687. PMC 8142898. PMID 32106218.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Colibactin&oldid=1255654455"